Consensus, the leading enterprise Product Experience Platform, announced a new partnership with Highspot, the only unified sales enablement platform that provides a system of record for go-to-market ...
NEW YORK CITY, NY / ACCESS Newswire / February 4, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
NEW YORK CITY, NY / ACCESS Newswire / January 31, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of ...
Sage Therapeutics Stock Down 1.4 % SAGE opened at $7.25 on Friday. The firm has a market cap of $443.48 million, a P/E ratio of -1.30 and a beta of 0.91. Sage Therapeutics has a 52 week low of $4. ...
The board of Sage Therapeutics unanimously rejected Biogen's acquisition offer of around $469 million, saying it "significantly undervalues" the company. That's not surprising – Sage filed a ...
Zacks.com on MSN2d
Analysts Estimate Sage Therapeutics, Inc. (SAGE) to Report a Decline in Earnings: What to Look Out forWall Street expects a year-over-year decline in earnings on lower revenues when Sage Therapeutics, Inc. (SAGE) reports results for the quarter ended December 2024. While this widely-known consensus ...
Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...
Sage Therapeutics rejected a takeover offer from Biogen (BIIB) and said it started a process to review its strategic alternatives. Sage rose 5.6%. Diversified Energy (OTCQX:DEC) +2.6% pre-market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback